Citations
Every cited fact in this deepdive traces back to one of the 330 sources below. Trust tier visible at a glance.
No citations at this trust level.
GLP1Evolution · medium trust · accessed 2026-05-22
Eden: $149 first month, then $229/mo for semaglutide; $249 first month, then $329/mo for tirzepatide. Embody: $149/month price-locked. ShedRx: broadest formulary.
Eden Health · high trust · accessed 2026-05-22
500mg NAD+: $119 first month then $186/mo (3-month plan). 1000mg: $145 first month then $226/mo. Disclaimer: 'The FDA does not review or approve any compounded medications for safety or effectiveness.'
Eden Health · high trust · accessed 2026-05-22
Product menu: GLP-1, Sermorelin, NAD+ injections, NAD+ face cream + nasal spray, MIC+B12. Disclaimer: 'Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.'
Mochi Health · high trust · accessed 2026-05-22
Base membership: $79/mo. Add-on: compounded injectable semaglutide +$99/mo, tirzepatide +$199/mo. Footer: 'All professional medical services are provided by licensed physicians and clinicians affiliated with independently owned and operated professional practices.'
MobiHealthNews · medium trust · accessed 2026-05-22
Eli Lilly filed lawsuits against Mochi Health, Fella & Delilah Health, Willow Health Services, and Henry Meds for misrepresenting tirzepatide-based weight loss treatments. Mochi allegedly switched patients to compounded tirzepatide with niacinamide additives and different doses at least five times in eight months.
Frier Levitt LLP · high trust · accessed 2026-05-22
Eli Lilly's complaints assert Corporate Practice of Medicine violations, false advertising, and unlawful prescription practices including 'modifying patient prescriptions en masse for business reasons.'
Medical Foundation of NC · low trust · accessed 2026-05-22
FDA Warning Letter #721455 dated Feb 20 2026 cited 'misbranding violations.' MEDVi founder publicly disputed; flagged domain (medvi.io) was 'operated by an affiliate marketing agency.' OpenLoop data breach Jan 2026: ~1.6M patient records; 68,160 confirmed in Texas.
U.S. Food and Drug Administration · high trust · accessed 2026-05-22
FDA warning letter index confirming Feb 20, 2026 letter to MEDVi (721455) and parallel Better Health Labs/Measured letter (721454). The Feb 6 2026 announcement: HHS General Counsel announced agency referred Hims & Hers to DOJ.
UT Cardiothoracic Surgery · low trust · accessed 2026-05-22
MEDVi compounded semaglutide injection: $179 first month, $299 refills. Tirzepatide injection: $349/mo. Oral tablets start $249/mo.
Vaccine Alliance · low trust · accessed 2026-05-22
Henry Meds compounded injectable semaglutide: $297/mo standard, $247/mo on 6-month plan, $197/mo on 12-month prepay. Patients on 1.7-2 mg dose pay $397/mo.
SeekPeptides · low trust · accessed 2026-05-22
Willow has been accused of selling tirzepatide in 'cosmetic' form. Henry Meds and Fella Health accused of selling tirzepatide in pill form, never approved by the FDA.
Willow Health · high trust · accessed 2026-05-22
$399/month, injectable only (subcutaneous, once weekly), HSA/FSA eligible. Footer: 'The products offered by Willow are compounded medications…not approved by the U.S. Food and Drug Administration (FDA) and have not undergone clinical trials.'
CNBC · high trust · accessed 2026-05-22
March 9, 2026: Novo Nordisk voluntarily dismissed without prejudice. Hims & Hers stock climbed more than 40% in early trading.
BioPharma Dive · high trust · accessed 2026-05-22
Hims gains access to Novo's Ozempic and both injectable and pill versions of Wegovy at competitor telehealth rates. Hims will discontinue compounded GLP-1 ads; existing patients offered transition to FDA-approved alternatives.
Frier Levitt LLP · high trust · accessed 2026-05-22
FDA timeline: Sept 2025 (~100 cease-and-desist letters), Feb 20 2026 (30 Warning Letters, public March 3 2026). Hims-Novo deal (March 9 2026).
Grafa · medium trust · accessed 2026-05-22
Q1 2026 revenue $608.1M (+4% YoY from $586M). Net loss $92.1M ($0.41/share) vs $49.5M net income Q1 2025. Gross margin fell from 73% to 65%. Adjusted EBITDA $44.3M (down from $91.1M). 2.6M subscribers, 9% YoY growth.
Yahoo Finance · medium trust · accessed 2026-05-22
Gross margin compression driven by strategic move away from compounded semaglutide. $33.5M restructuring including inventory write-downs. Collaborations with Novo Nordisk and Eli Lilly to provide FDA-approved options to 2.6M subscribers.
Telehealth.org · medium trust · accessed 2026-05-22
Named recipients: Bliv Wellness, Belle Health, FitRX, BluefitMD, Viv Health, 24HrDoc, GoodGirlRx. Second wave following 100+ Sept 2025 letters. 15 days to respond.
Patient Care Online · medium trust · accessed 2026-05-22
30 warning letters issued Feb 20 2026. Primary violations: claims implying sameness with FDA-approved products, obscuring product sourcing.
STAT News · high trust · accessed 2026-05-22
Four nationwide medical groups affiliated with at least 30% of warned companies: Beluga Health, OpenLoop, MD Integrations, and Telegra. More than 70 telehealth companies warned by FDA in last six months.
NPR · high trust · accessed 2026-05-22
April 23, 2025: Eli Lilly filed lawsuits against Mochi Health, Fella Health, Willow Health, and Henry Meds for selling compounded tirzepatide as legitimate alternatives to Zepbound and Mounjaro.
Lengea Law · medium trust · accessed 2026-05-22
September 8, 2025: U.S. District Judge Andre Birotte Jr. dismissed Eli Lilly's lawsuit against Willow Health. Court found Lilly failed to show any patients or physicians switched from branded products.
McDermott Will & Emery · high trust · accessed 2026-05-22
May 7, 2025: US District Court Northern District of Texas upheld FDA's removal of tirzepatide from the drug shortage list. Court concluded FDA 'acted within its statutory authority.'
Frier Levitt LLP · high trust · accessed 2026-05-22
OFA v. FDA: Judge Pittman entered sealed order March 5, 2025 denying preliminary injunction. May 7, 2025 ruling upheld FDA's shortage-resolution determination.
National Law Review · high trust · accessed 2026-05-22
April 1, 2026: FDA statement clarifying compliance policy on 503A and 503B exemptions. Preserves patient-specific 503A compounding when prescribed for individual patient AND not essentially copies. 'Significant difference' must be patient-specific and documented by prescriber. First time FDA expressly stated what it considers essentially a copy.
Med Spa Standards · low trust · accessed 2026-05-22
Post-shortage 503A exceptions: documented patient-specific clinical need (e.g., polysorbate-80 allergy) or clinically required dose strength. 'Cost savings does not qualify.'
Stevens & Lee · high trust · accessed 2026-05-22
Alabama AG (Nov 10 2025): TRO against Aurora IV & Wellness. Connecticut AG (May 21 2025): statewide notice; 'generic Ozempic' terms violate CUTPA; settled with Triggered Brand. Over 40 state AGs sent joint letter to FDA in 2025.
Pharmaceutical Commerce · medium trust · accessed 2026-05-22
Noom Microdose GLP-1Rx Program launched March 31, 2026. Initial 4-week subscription $79 + tax, then $199/mo on 12-week plan.
Noom · high trust · accessed 2026-05-22
$79 first 4-week intro, then $199/mo 12-week. Disclaimer: 'If your clinician feels compounded medications are clinically appropriate for you, any compounded medications are not approved by the FDA.'
Telehealth Ally · medium trust · accessed 2026-05-22
Henry Meds: $149 sema / $349 tirz. Ro: $149 sema / $399 tirz. Noom: $149 sema. Hims: brand only post-2026 exit. LillyDirect: $299 Zepbound.
eMarketer · medium trust · accessed 2026-05-22
Ro patients can get 2.5 mg Zepbound vials at $399/mo and 5 mg vials at $549/mo. LillyDirect offers 7.5/10/12.5/15 mg KwikPen doses at $449/mo.
VirtualCareFinder · low trust · accessed 2026-05-22
Ro Body Program: all 50 states. Found Health: ~48 states. Noom Med: ~40 states. Calibrate: ~40 states. WeightWatchers Clinic: ~23 states.
Good Life Meds · high trust · accessed 2026-05-22
Product menu: compounded tirzepatide / semaglutide / microdose / oral, brand Wegovy / Zepbound / Ozempic / Mounjaro, sermorelin, NAD+, MIC+B12, glutathione, B12, sildenafil, tadalafil, hair regrowth. NAD+ has no FDA-approved commercial equivalent.
Orrick, Herrington & Sutcliffe LLP · high trust · accessed 2026-05-22
April 15, 2026: FDA announced removal of 12 peptides from Category 2. 'Removal from Category 2 does not, by itself, place these substances on the 503A bulks list or into Category 1.' PCAC meetings July 23-24, 2026 and February 2027.
FDA Law Blog (Hyman, Phelps & McNamara) · high trust · accessed 2026-05-22
April 16, 2026 Federal Register notice. July 23-24 2026 PCAC: BPC-157, KPV, TB-500, MOTs-C, Emideltide (DSIP), Semax, Epitalon. February 2027 PCAC: GHK-Cu, Melanotan II, Cathelicidin (LL-37), Dihexa acetate, Mechano Growth Factor, PEG-MGF. PCAC review is 'likely a necessary procedural step, not the finish line.'
Tactus Health · medium trust · accessed 2026-05-22
Tactus only prescribes peptides that are legally compoundable through FDA-registered pharmacies — sermorelin and PT-141. BPC-157, CJC-1295, and ipamorelin on FDA's Category 2 and Tactus does not prescribe those.
Corepay · medium trust · accessed 2026-05-22
'Most low-risk payment providers like Square, Stripe, and Boulevard do not support GLP-1 sales.' GLP-1s are 'high-risk category.' LegitScript certification required by acquiring banks.
Kendall PC · medium trust · accessed 2026-05-22
'Platforms like Stripe, PayPal, and Square often freeze accounts tied to peptide sales.' Payment processors expanding 'blacklists' for unapproved peptides.
McDermott Will & Emery · high trust · accessed 2026-05-21
FDA declared semaglutide shortage 'resolved' on February 21, 2025. 503A: April 22, 2025. 503B: May 22, 2025. Facilities must ensure semaglutide products either differ in dosage strength or route, or include documented prescriber determinations showing 'significant difference.'
Harris Beach Murtha PLLC · high trust · accessed 2026-05-21
Tirzepatide 503A: Stop compounding immediately. 503B: March 19, 2025. Semaglutide 503A: April 22, 2025; 503B: May 22, 2025.
Foley & Lardner LLP · high trust · accessed 2026-05-21
April 1, 2026 clarification: 503A compounders may fill up to four prescriptions per calendar month. Compounded GLP-1 is 'essentially a copy' when it has the same API in similar strength (within 10%) and same administration route. Combinations like semaglutide-plus-vitamin-B12 fall within 'essentially a copy' when active ingredient is within 10% of commercial product.
Pharmacy Times · high trust · accessed 2026-05-21
April 30, 2026 proposed rule to formally exclude semaglutide, tirzepatide, and liraglutide from 503B bulk drug substances list. Public comment closes June 29, 2026. Cites 455+ adverse event reports for compounded semaglutide and 320+ for tirzepatide.
Spencer Fane LLP · high trust · accessed 2026-05-21
FDA issued over 55 warning letters on September 16, 2025 targeting online sellers of compounded GLP-1 medications.
Fagron Academy · medium trust · accessed 2026-05-21
September 2023 revisions: 503A Category 2 includes AOD-9604, BPC-157, ipamorelin acetate, kisspeptin-10. 503A Category 1 includes vasoactive intestinal peptide and GHK-Cu (non-injectable). 503B Category 2 includes ipamorelin acetate; Category 1 includes gonadorelin acetate and GHRP-2.
Anderson Triggs (law firm) · medium trust · accessed 2026-05-21
FDA announced September 27, 2024: ibutamoren mesylate, BPC-157, ipamorelin acetate, CJC-1295, AOD-9604, thymosin alpha-1, thymosin beta-4 removed from Cat 2. Ipamorelin acetate PCAC October 29, 2024; CJC-1295/AOD-9604/Thymosin Alpha-1 December 4, 2024.
Safe HG · low trust · accessed 2026-05-21
Evexias Medical Group and Farmakeio sued FDA late 2023 challenging Sept 2023 Category 2 reclassification of 17 peptides. September 2024 settlement: FDA agreed to halt unilateral ban and submit key peptides for PCAC review.
Lengea Law · medium trust · accessed 2026-05-21
Seven peptides under PCAC review July 23-24, 2026: BPC-157, KPV, TB-500, MOTs-C (July 23); DSIP/Emideltide, Semax, Epitalon (July 24). PCAC provides 'advisory recommendations only.' 'No fixed deadline exists.'
Frier Levitt · high trust · accessed 2026-05-21
FDA released final interim guidances January 7, 2025. After that date, FDA will no longer categorize newly-nominated bulk drug substances. 'Interim compounding' for new nominated substances is cut off.
Hinshaw & Culbertson LLP · high trust · accessed 2026-05-21
Effective July 1, 2026: PIC must be California-licensed and 'employed by, and actively working at, the non-resident pharmacy,' complete Board PIC training within two years. Toll-free patient access: minimum 40 hours/week across 6 days. CURES reporting Schedule II-IV within one business day. Sterile compounding license fees approximately $8,500.
CompHealth · medium trust · accessed 2026-05-21
IMLC operates in 43 states plus DC and Guam in 2026. States not in IMLC: Alaska, Arkansas, California, Florida, Oregon, North Carolina, South Carolina. New York has enacted but not yet implemented.
TrimRX · low trust · accessed 2026-05-21
California, Texas, Florida, New York, Washington enforce most aggressively. Texas has prosecuted salt-form tirzepatide cases. Florida 'mandates synchronous (video/phone) telehealth visits.'
Healthon · low trust · accessed 2026-05-21
Sermorelin was approved for short stature associated with growth hormone deficiency (Geref, NDA 020443). Discontinued by manufacturer in 2008 for commercial reasons, not safety. Compoundable under 503A via component-of-FDA-approved-drug pathway.
Federal Register / DEA · high trust · accessed 2026-05-21
May 12, 2023 through December 31, 2026: DEA-registered practitioner authorized to prescribe schedule II-V controlled substances via telemedicine without in-person evaluation.
Telehealth.org · medium trust · accessed 2026-05-21
For noncontrolled substances 'there is no federal in-person exam requirement, no DEA involvement, and no special telemedicine-specific prescribing restrictions.'
Center for Connected Health Policy · medium trust · accessed 2026-05-21
State requirements vary materially. Alabama: physician duty of care same in-person or via telehealth. Arkansas: requires in-person or real-time audio-video examination.
California State Board of Pharmacy · high trust · accessed 2026-05-21
California requires non-resident pharmacy license + current and valid resident-state license. Effective 7/1/2026: PIC must be California-licensed pharmacist employed and working at the non-resident pharmacy.
Texas State Board of Pharmacy · high trust · accessed 2026-05-21
Texas requires non-resident pharmacies to verify the pharmacy facility license from the Resident Board, plus a recent inspection report. Class E-S separate. Board may require surety bond.
Florida Board of Pharmacy · high trust · accessed 2026-05-21
Non-resident pharmacy permit applications must be submitted to deliver dispensed medicinal drug into Florida. Non-resident sterile compounding permits available separately.
Harbor Compliance · medium trust · accessed 2026-05-21
All states require non-resident pharmacy license in states they ship to. Massachusetts does not offer out-of-state licenses except for outsourcing facilities. Illinois pharmacy license fee $600; Georgia non-resident application fee $1,000.
U.S. Securities and Exchange Commission (EDGAR) · high trust · accessed 2026-05-21
Affiliated Medical Groups are 'separate professional corporations or other professional entities owned solely by licensed physicians.' Hims 'serve[s] as an administrative services manager for the Affiliated Medical Groups for the non-clinical aspects of their operations and receive[s] a fixed administrative fee.' Arrangements 'generally have initial ten-year terms with renewal options.'
Epstein Becker Green · high trust · accessed 2026-05-21
Survey examines state restrictions on CPOM across all 50 states and DC. Third Edition May 15, 2024.
MedPath Compliance · medium trust · accessed 2026-05-21
Classifies states as Strict (AZ, CA, CO, IL, MA, MI, NJ, NY, PA, TX, WA), Moderate, Permissive. California: 'Corporations and other artificial entities shall have no professional rights' (Bus. & Prof. Code § 2400). Texas: 'one of the strictest doctrines.'
Permit Health · medium trust · accessed 2026-05-21
In friendly PC model, business leadership is given right to choose the physician PC owner. MSA outlines how MSO services the PC. Identifies 34 CPOM states; particularly strict include California, Texas, New York, North Carolina, and Nevada.
MedCity News · medium trust · accessed 2026-05-21
Three compliance-risk areas: CPOM, fraud & abuse, data privacy. MSA must designate PC as solely responsible for clinical decisions; explicitly list management services; state fee structure. Compliant approach: fixed fee at FMV. Risky: fees tied to referral metrics, percentage-based compensation.
Eisner Gorin LLP · medium trust · accessed 2026-05-21
CA B&P Code §650 prohibits licensed healthcare professionals from offering, paying, soliciting, or receiving anything of value in exchange for patient referrals. 'Applies to all healthcare services in California, including cash-pay med spa treatments.' Felony penalties up to 3 years plus $50,000 per violation.
Norman Spencer Law Group · medium trust · accessed 2026-05-21
NY Education Law §6530(19) prohibits sharing fees with unlicensed person as quid pro quo for patient referrals. §6530(18) prohibits 'directly or indirectly offering, giving, soliciting, or receiving any fee or other consideration to or from a third party for the referral of a patient.'
Nixon Peabody LLP · high trust · accessed 2026-05-21
Signed June 9, 2025. Existing OR MSOs comply by Jan 1, 2029; new MSOs Jan 1, 2026. Prohibits MSO shareholders/directors/members/managers from owning majority of PME. Exempt: hospitals, out-of-state telemedicine companies.
Foley & Lardner LLP · high trust · accessed 2026-05-21
Telemedicine exemption: 'entities engaged in the practice of telemedicine that do not have a physical location where patients receive clinical services in Oregon.' Compliance dates: Jan 1, 2026 for new MSOs; Jan 1, 2029 for existing.
Epstein Becker Green / Health Law Advisor · high trust · accessed 2026-05-21
Signed October 6, 2025; effective January 1, 2026. Prohibits private equity groups and hedge funds from interfering with provider judgment. Violating contracts 'deemed void.' Enforcement by state AG.
Sidley Austin LLP · high trust · accessed 2026-05-21
SB 351 applies to 'physician and dentist management platforms operated by private equity groups and hedge funds.' Restrictions 'closely track' California Medical Board guidance.
Holland & Knight LLP · high trust · accessed 2026-05-21
Art Center Holdings, Inc. v. WCE CA Art, LLC (LA County Superior Court Case No. 24SMCV01185, 2024). Court granted receivership transferring SCRC control back to Dr. Surrey, finding Continuity Agreement's 'broad terms' violated California law.
Faegre Drinker Biddle & Reath LLP · high trust · accessed 2026-05-21
California AG filed amicus brief in Art Center Holdings v. WCE CA Art (Mar 30, 2026), urging strict CPOM interpretation. AG considers problematic agreements that grant 'unchecked authority' or allow MSOs to 'effectuate a physician ownership change' with broad discretion.
Frier Levitt LLC · high trust · accessed 2026-05-21
Eli Lilly's complaints against Fella Health and Mochi Health allege violations of state CPOM laws, with complaints detailing how non-physician founders and executives exert control over medical decision-making. The legal test in CPOM is operational substance, not contract drafting.
The Hill · medium trust · accessed 2026-05-21
Eli Lilly accused Mochi Health and Fella Health of engaging in the corporate practice of medicine, claiming neither is owned by a physician and that the telehealth companies exert influence over their 'independent' affiliated medical groups.
Interstate Medical Licensure Compact Commission · high trust · accessed 2026-05-21
The Compact currently includes 40 states, DC, and Guam. Physicians who qualify can obtain a new license in an average of 19 days, with 51% issued within a week.
DirectShifts · medium trust · accessed 2026-05-21
IMLC application fees range $200–$500 with processing typically 4–8 weeks per state; state licenses cost $300–$1,000 per state with processing 2–6 months.
HHS Office of Inspector General · high trust · accessed 2026-05-21
The federal AKS is a criminal law that prohibits payment of 'remuneration' to induce or reward patient referrals involving any item or service payable by the Federal health care programs. Safe harbors protect certain payment and business practices.
DLA Piper · high trust · accessed 2026-05-21
OIG Advisory Opinion 25-03 (June 6, 2025) approved an MSO-PC telehealth arrangement involving lease fees and administrative service fees. AKS personal services and management contracts safe harbor can protect MSO-PC arrangements.
Permit Health · medium trust · accessed 2026-05-21
New Jersey prohibits CPOM through case law. Does NOT permit PLLC — only PC, plus LLCs wholly-owned by licensed professionals. Insurance fraud claims for noncompliant arrangements carry triple damages.
Permit Health · medium trust · accessed 2026-05-21
Florida does not have CPOM doctrine. Health Care Clinic License required for non-physician-owned medical practices that bill insurance. Operating without it is third-degree felony; penalties up to $5,000/day.
Texas Legislature Online · high trust · accessed 2026-05-21
Texas Occupations Code Chapter 162 regulates physician practice via certified nonprofit health corporations. Texas identified as having 'one of the strictest CPOM doctrines.'
American Bar Association Health Law Section · high trust · accessed 2026-05-21
Four states (Florida, New York, North Carolina and Tennessee) have notably broad prohibitions against fee splitting.
Manatt Health · high trust · accessed 2026-05-21
Texas's fee-splitting prohibition under §3.07(c) is narrower than CA/NY/FL. New Jersey has no statutory fee-splitting prohibition, though CPOM is strongly enforced through PC ownership requirements.
New York State Education Department · high trust · accessed 2026-05-21
New York's CPOM prohibition operates through Education Law §6522 and Public Health Law §2806. NY permits both PCs and PLLCs but restricts multi-professional ownership.
Health Care Law Brief · medium trust · accessed 2026-05-21
Friendly PC structures use interlocking contracts: MSA, Stock Transfer Restriction Agreement, physician employment/services agreement. TRA terms commonly require physician to transfer shares to MSO-designated successor at nominal price ($1-$100).
Marti Law Group · medium trust · accessed 2026-05-21
Some states require physician practices to form PCs and do not permit PLLCs. New York permits both PCs and PLLCs but restricts multi-professional ownership.
Stripe · high trust · accessed 2026-05-21
Last Updated: 2026-05-13. Restricted: 'Telemedicine and telehealth services'; 'Card-not-present prescription-only products and pharmaceuticals'. Prohibited: 'Pseudo-pharmaceuticals or nutraceuticals that are not safe or make harmful claims'.
Shopify · high trust · accessed 2026-05-21
Regulated products include 'Prescription drugs, medical devices'. Pseudo pharmaceuticals: 'Pharmaceuticals and other products that make health claims that are not verified by a local or national regulatory body.'
Platter · low trust · accessed 2026-05-21
'Shopify groups peptides under several restricted categories in its Acceptable Use Policy.'
Square (Block, Inc.) · high trust · accessed 2026-05-21
Prohibited: 'internet/mail order/telephone order pharmacies or pharmacy referral services (where fulfillment of medication is performed with an internet or telephone consultation, absent a physical visit).'
PayPal · medium trust · accessed 2026-05-21
PayPal prohibits transactions involving 'narcotics, steroids, certain controlled substances or other products that present a risk to consumer safety,' drug paraphernalia, and dietary supplements 'promoted on its label or in its labeling as a treatment, prevention, or cure for a specific disease.'
U.S. Food and Drug Administration · high trust · accessed 2026-05-21
FDA reviewed Hims & Hers' website content August 2025; cited misleading direct-to-consumer marketing with claims including 'Same active ingredient as Ozempic and Wegovy' and 'Clinically proven ingredients.'
onPoint Studio · low trust · accessed 2026-05-21
Easy Pay Direct: requires LegitScript, integrates Authorize.net/NMI. Corepay: 24-72hr pre-approval, LegitScript required, supports GLP-1s. AllayPay: optional LegitScript, 'rolling reserves typically 10%, released after 3-6 months.'
SeamlessChex · low trust · accessed 2026-05-21
Credit Card: '2.95% to 5.5%'. ACH/eCheck: 'Under 2%'. Rolling reserve: '10% held 3-6 months.' Prohibits 'semaglutide/tirzepatide/retatrutide drug names per FDA guidance.'
Paycron · low trust · accessed 2026-05-21
'High-risk processing fees for peptide merchants range from 3.5% to 6.0% per transaction, with a mandatory rolling reserve of 5% to 10% held for 180 days.'
SoarPay (Soar Payments LLC) · low trust · accessed 2026-05-21
'If you are selling medicine or similar services online you will need to provide copy of VIPPS Certification or proof of registration with LegitScript.'
LegitScript LLC · high trust · accessed 2026-05-21
Healthcare certification 'Get qualified to advertise on Google, Microsoft, Meta, LinkedIn, TikTok, and more.' Three certification programs: Addiction Treatment, Healthcare, CBD.
Optimized Payments · medium trust · accessed 2026-05-21
Merchants 'Excessive' = 2.2% combined fraud + dispute ratio (2025), tightening to 1.5% on April 1, 2026 for U.S., Canada, EU. Effective April 1, 2025 with six-month advisory; enforcement October 1, 2025.
Chargeback Gurus · medium trust · accessed 2026-05-21
VAMP consolidates VDMP and VFMP into single program effective April 1, 2025. Merchant minimum 1,500 events/month for inclusion.
Chargeback Gurus · medium trust · accessed 2026-05-21
ECM threshold: '100 or more monthly chargebacks and their ratio exceeds 1.5% for two consecutive months.' Fines: Month 2 $1,000; Month 3 $1,000; Months 4-6 $5,000. Issuer Recovery Assessment: '$5 USD/EUR for each chargeback after the first 300.'
InclusivePay · low trust · accessed 2026-05-21
'A research peptide seller processing $18K per month had their Stripe account terminated with no warning. Their $11,200 in pending payouts was frozen for 127 days.'
Merchant Maverick · medium trust · accessed 2026-05-21
'Mercury is also unavailable to some businesses classified as high-risk.' 'Additional complaints on the BBB site involve account closures and difficulty accessing funds.'
GrowthHQ · low trust · accessed 2026-05-21
Mercury closed accounts en masse by August 22, 2024. Closure process: 'compliance email, freezing all transactions, and holding funds for up to 60 days.'
JPMorgan Chase · high trust · accessed 2026-05-21
March 2026 NACHA rule changes require businesses to strengthen fraud monitoring for ACH transactions.
SeamlessChex · low trust · accessed 2026-05-21
Crypto options including 'VERIFIED Crypto Checkout charges a flat 4%' and 'Coinbase Commerce' are usable. Bank-side cash-out conversion remains exposed to AML scrutiny.
Wiley Rein LLP · high trust · accessed 2026-05-21
Interim final rule issued March 21, 2025, published March 26, 2025. Exempts all domestic U.S. companies and their beneficial owners; U.S. persons as beneficial owners of foreign companies. Reporting universe shrank from ~32 million to ~12,000 entities.
Wolters Kluwer · high trust · accessed 2026-05-21
IFR effective March 26, 2025. U.S. companies and U.S. persons exempt from BOI reporting.
Sidley Austin LLP · high trust · accessed 2026-05-21
IFR adopted March 21, 2025. Only foreign entities registered to do business in U.S. states/tribes with non-U.S. person beneficial owners must file.
Crowell & Moring LLP · high trust · accessed 2026-05-21
January 23, 2025: U.S. Supreme Court granted stay of Texas Top Cop Shop injunction. Affected companies are not required to report beneficial ownership information at this time.
Bay Legal PC · medium trust · accessed 2026-05-21
Moscone-Knox Professional Corporation Act (CA Corp Code §§13400-13410) requires licensed professionals to organize as professional corporation. CA Corp Code §17701.04 bars LLCs from rendering professional services unless expressly authorized.
California Legislature / Justia · high trust · accessed 2026-05-21
California Corp Code §13400 et seq. authorizes professional corporations for licensed professionals; Moscone-Knox Act governs formation, ownership, and operation.
Texas Legislature · high trust · accessed 2026-05-21
Texas BOC Chapter 301 establishes universal professional entity requirements; §301.006 mandates only licensed professionals may provide professional services.
Texas Secretary of State · high trust · accessed 2026-05-21
Form 304 application for foreign LLCs to register in Texas; filing fee $750 one-time.
Northwest Registered Agent · medium trust · accessed 2026-05-21
Filing fee for Application for Registration of Foreign LLC with Texas Secretary of State is $750.
US Legal · medium trust · accessed 2026-05-21
NY LLCL §1207(b) requires each member of medical PLLC be licensed under NY Education Law Article 131.
New York Department of State · high trust · accessed 2026-05-21
Within 120 days after filing Application for Authority, foreign LLC must publish in two newspapers once a week for six weeks. Processing fee $250, Certificate of Publication $50.
New York Department of State · high trust · accessed 2026-05-21
All foreign LLCs in New York must file Biennial Statement every other year during anniversary month. Filing fee $9.
Florida Legislature · high trust · accessed 2026-05-21
Chapter 621 governs Florida professional corporations and PLLCs. Medical PLLC must have only licensed physicians as members.
Dean Mead · medium trust · accessed 2026-05-21
PCs and PLLCs can be organized under Chapters 607/621 and 608/621 in Florida for professional medical practices.
Florida Department of State · high trust · accessed 2026-05-21
Foreign LLC formed in another state must file Application for Authorization and pay $125 registration fee. Annual report 2026 $138.75 due May 1; $400 late penalty.
Tailor Brands · medium trust · accessed 2026-05-21
PLLCs governed by 15 Pa.C.S. Chapter 88. Annual registration fee $610 per member (minimum $500) due April 15.
Permit Health · medium trust · accessed 2026-05-21
Pennsylvania strictly enforces CPOM, requiring all ownership interests reside with licensed physicians.
Illinois General Assembly · high trust · accessed 2026-05-21
Under 805 ILCS 185/13, all managers of medical PLLC must be licensed under Medical Practice Act of 1987.
Illinois General Assembly · high trust · accessed 2026-05-21
Illinois Professional Service Corporation Act governs PCs in Illinois.
New Jersey Legislature · high trust · accessed 2026-05-21
N.J.S.A. 14A:17-1 et seq. requires all shareholders of NJ professional corporation be licensed in same or closely allied professional services.
Schenck, Price, Smith & King LLP · high trust · accessed 2026-05-21
New Jersey strictly enforces CPOM through N.J.A.C. §13:35-6.16, requiring 100% physician ownership. NJ does not use 'PLLC' designation but permits healthcare LLCs under N.J.A.C. 13:42-7.2.
Michigan Legislature · high trust · accessed 2026-05-21
A professional limited liability company may render professional services, each member and manager must be licensed.
Ohio Legislative Service Commission · high trust · accessed 2026-05-21
Licensed physicians may render professional medical services through LLC formed under Chapter 1705 or 1706, or through professional association formed under Chapter 1785.
Virginia Legislature · high trust · accessed 2026-05-21
Virginia Code Title 13.1, Chapter 7 requires PC shareholders be 'duly licensed.' Chapter 13 imposes identical requirements on PLLC members.
North Carolina Medical Board · high trust · accessed 2026-05-21
In compliance with NCGS 55B, must obtain prior approval from NC Medical Board for ownership change. Application fee $50, renewal $25.
Little Health Law · medium trust · accessed 2026-05-21
Georgia does not offer PLLC option. Professionals create LLCs or PCs. PC formation requires initial approval from Georgia Composite Medical Board.
Georgia General Assembly · high trust · accessed 2026-05-21
Georgia Code Title 14, Chapter 7 governs Professional Corporations.
Delaware Division of Corporations · high trust · accessed 2026-05-21
Certificate of Formation filing fee for LLC is $110.
Delaware Division of Corporations · high trust · accessed 2026-05-21
All Delaware LLCs required to pay annual tax of $300, due on or before June 1. NOT required to file annual report.
Wyoming Secretary of State · high trust · accessed 2026-05-21
All Wyoming LLCs must pay annual report license tax, minimum $60 or $0.0002 per dollar of assets, whichever is greater.
Wyoming Secretary of State · high trust · accessed 2026-05-21
Wyoming SOS filing fee for Articles of Organization of LLC is $100.
Wyoming Legislature · high trust · accessed 2026-05-21
Section 17-29-503(g) provides exclusive remedy by which person seeking to enforce judgment may satisfy judgment, including sole member, dissociated member or transferee.
Wyoming LLC Attorney · medium trust · accessed 2026-05-21
Wyoming precludes creditors from any legal or equitable remedy other than charging order against LLC interest, even as to Single-Member LLCs.
Tarro Law · medium trust · accessed 2026-05-21
Wyoming stands out as top-tier charging order jurisdiction with statutory exclusivity for both single-member and multi-member LLCs.
California Franchise Tax Board · high trust · accessed 2026-05-21
Every LLC doing business or organized in California must pay annual tax of $800. LLCs with CA-source income $250K+ pay graduated additional fee.
UpCounsel · low trust · accessed 2026-05-21
Cost to register foreign LLC in California includes $70 state filing fee and $20 Initial Statement of Information fee.
New Mexico Taxation and Revenue Department · high trust · accessed 2026-05-21
GRT imposed on businesses for privilege of doing business in New Mexico. Deduction for administrative/accounting services under §7-9-69 NMSA 1978 only if services performed by affiliate on nonprofit or cost basis.
New Mexico Taxation and Revenue Department · high trust · accessed 2026-05-21
FYI-202 is NM TRD's guidance on GRT applicability to health care services. MSA fee between non-affiliate MSO and PC is generally taxable receipt of services.
Hawaii Department of Taxation · high trust · accessed 2026-05-21
Hawaii GET applied directly to businesses on total income. State rate 4% across all islands; county surcharges up to 0.5%.
Hawaii Department of Taxation · high trust · accessed 2026-05-21
Wholesale rate 0.5% applies to business-to-business sales or intercompany transfers. Narrow exemption for intercompany services and common paymaster payroll arrangements.
Washington Department of Revenue · high trust · accessed 2026-05-21
Under Washington B&O tax, every legal entity is separate taxpayer. Intercompany transactions generally subject to B&O tax.
Washington Department of Revenue · high trust · accessed 2026-05-21
Washington B&O tax classifications including 'Service and Other Activities' captures management services provided by MSO to PC.
Reed Smith LLP · high trust · accessed 2026-05-21
On audit, Department sources portion of ServiceCo's intercompany receipts from OpCo to Washington, resulting in B&O tax liability.
South Dakota Department of Revenue · high trust · accessed 2026-05-21
South Dakota imposes 4.5% state sales tax on services unless specifically exempted.
Avalara · medium trust · accessed 2026-05-21
South Dakota, Hawaii, New Mexico, and West Virginia are four states that tax services by default.
Internal Revenue Service · high trust · accessed 2026-05-21
Form SS-4 is used to apply for an EIN.
Internal Revenue Service · high trust · accessed 2026-05-21
Online application via IRS EIN Assistant issues EIN instantly. Responsible Party must be individual, not entity.
Vogt | Resnick | Sherak, LLP · medium trust · accessed 2026-05-21
Personal guarantees commonly used for commercial leases, lines of credit, or loans. Allows creditors to pursue personal assets despite LLC separation.
Keck Legal · medium trust · accessed 2026-05-21
Personal guarantee allows landlord to legally pursue founders' personal assets to satisfy lease debt, including seizing personal bank accounts, placing liens, and garnishing wages.
Attorney Aaron Hall · medium trust · accessed 2026-05-21
If shareholders signed personal guarantee on loan or merchant account, they have voluntarily agreed to forego protection of corporate veil.
Internal Revenue Service · high trust · accessed 2026-05-21
Member of partnership, LLC, or LLP may be liable for TFRP under IRC §6672. Any owner, officer, manager or employee with control over tax/financial affairs is responsible party.
McGlinchey Stafford PLLC · high trust · accessed 2026-05-21
Joint and several liability attaches to each responsible party, meaning each can be held liable for the entire amount of unpaid trust-fund taxes.
California Department of Tax and Fee Administration · high trust · accessed 2026-05-21
CDTFA may pursue collection action against certain corporate or LLC personnel for unpaid sales and use tax liability.
Brinen & Associates · medium trust · accessed 2026-05-21
New York defines responsible persons broadly: owners, officers, directors, employers, members, partners, managers or employees under duty to act for business in sales and use tax compliance.
Vogt | Resnick | Sherak, LLP · medium trust · accessed 2026-05-21
Courts examine commingling of funds, observance of corporate formalities, capitalization adequacy, arm's-length transactions, confused records.
Adishian Law · medium trust · accessed 2026-05-21
Non-compliance with corporate formalities may lead to application of alter-ego doctrine.
HCH Lawyers · medium trust · accessed 2026-05-21
Alter ego theory involves court's disregard for corporate entity and liability protection when individual and corporation cease to be separate.
HHS / Telehealth.HHS.gov · high trust · accessed 2026-05-21
Florida's Telehealth Provider Registry allows out-of-state providers to treat Floridian patients without Florida license, with registration.
HHS / Telehealth.HHS.gov · high trust · accessed 2026-05-21
About 20 states currently have telehealth registration process.
Wolters Kluwer · medium trust · accessed 2026-05-21
All states require online or mail-order pharmacies to have non-resident pharmacy license in states they ship to.
Cornell Law School / Legal Information Institute · high trust · accessed 2026-05-21
Notification 'without unreasonable delay and in no case later than 60 calendar days after discovery of breach' via first-class mail or email with consent.
Cornell Law School · high trust · accessed 2026-05-21
500+ breaches: notification contemporaneously with §164.404(a). Under-500: annual aggregate not later than 60 days after end of calendar year.
U.S. Department of Health & Human Services · high trust · accessed 2026-05-21
HIPAA Breach Notification Rule 45 CFR §§ 164.400-414 requires notification following breach of unsecured PHI. 500+ breaches posted on OCR public portal.
HIPAA Journal · medium trust · accessed 2026-05-21
2025: Tier 1 $145–$73,011; Tier 2 $1,461–$73,011; Tier 3 $14,602–$73,011; Tier 4 $73,011–$2,190,294. Annual cap $2,190,294. OCR enforcement discretion reduces practical caps to $36,505 / $146,053 / $365,052.
The Doctors Company · high trust · accessed 2026-05-21
'The Doctors Company is one of the only medical professional liability insurers licensed and insuring telemedicine in all 50 states.'
Mira Health · low trust · accessed 2026-05-21
Premium ranges: Nurse Practitioners $375-$1K, Physician Assistants $2K-3K, Physicians $5-$25K. Carriers: CM&F, The Doctors Company, ProAssurance, MedPro Group, Coverys.
Cunningham Group · medium trust · accessed 2026-05-21
Telemedicine malpractice insurance typically costs $5,000-$25,000 annually for physicians. Carriers: Medical Protective, The Doctors Company, NORCAL, ProAssurance, CNA, Coverys, PSIC, ISMIE, MAG Mutual.
Doctors Insurance Agency · medium trust · accessed 2026-05-21
Most peptides used in wellness and aesthetics are considered high-risk by most insurers. Required endorsements include explicit coverage for injectable/oral/compounded peptide protocols, regulatory defense. Omitting peptide services constitutes grounds for policy rescission or claim denial.
SeaPort Insurance Services · low trust · accessed 2026-05-21
Standard malpractice policies often exclude coverage for experimental treatments. GLP-1 weight loss treatments covered only with specific exception/exclusion endorsement.
DrsCoverage · low trust · accessed 2026-05-21
Tail coverage typically ranges from 150% to 300% of annual premium, paid upfront as one-time cost. MedPro Group offers free tail coverage at retirement after one year of insurance.
Drug & Device Law Blog (Reed Smith) · medium trust · accessed 2026-05-21
Texas Supreme Court Randol Mill Pharmacy v. Miller (2015) classified compounding pharmacists as healthcare providers for dispensing-related claims but excluded 'causes of action for the sale of mishandled or defective products.'
National Law Review · medium trust · accessed 2026-05-21
Pharmacy has no duty to warn customers of prescription drug side effects. Learned intermediary doctrine applies to pharmacists in the same way as drug manufacturers.
NORCAL Group (ProAssurance) · high trust · accessed 2026-05-21
'NORCAL Group medical professional liability policies exclude any liability that an insured has assumed under a written or oral contract or agreement, with few exceptions.'
Beazley · high trust · accessed 2026-05-21
Four core coverage pillars: Professional Liability, Technology & Media Liability, General Liability, Cyber Liability. Three insured categories: Providers, Platform Hosts (MSO profile), Software/Hardware Developers.
Beazley · medium trust · accessed 2026-05-21
BBR provides breach response services for up to 5,000,000 notified individuals per policy period, with separate dedicated limit up to $2.5M.
Admiral Insurance Group · medium trust · accessed 2026-05-21
Integrated virtual care insurance combines Medical Malpractice, Technology E&O, Media Liability, Cyber Coverage.
Gallagher · medium trust · accessed 2026-05-21
Modern public company D&O policies typically include bodily injury exclusion. Carve-back strategies: securities claims carve-back, Side A protection, Side A DIC policies.
Schlam Stone & Dolan · medium trust · accessed 2026-05-21
Regulatory exclusion bars coverage for losses from actions by government agencies like SEC and FDIC.
Healthie · high trust · accessed 2026-05-21
BAA automatically executed upon account creation. Effective date May 25, 2018. Governed by Delaware law. Breach notification within 'five (5) business days after discovery.'
Doxy.me · high trust · accessed 2026-05-21
Free and Professional accounts include BAA but limited to individual providers only. Multi-provider organizations must transition to Clinic account.
Spruce Health · medium trust · accessed 2026-05-21
Spruce HIPAA BAA is included automatically in standard terms for organizations. SOC 2 audited, HITRUST certified.
OpenLoop Health · medium trust · accessed 2026-05-21
Full-stack white-label infrastructure for telehealth brands. SOC 2 Type 1 certified, HIPAA compliant, signs BAAs.
Sentra · medium trust · accessed 2026-05-21
January 7-8, 2026: 716,000+ patients exposed across 120+ healthcare companies via single intrusion. Threat actor claims 1.6 million records. Vulnerability was aggregation without proper segmentation.
Telehealth.org · low trust · accessed 2026-05-21
3.1 million users notified of breach. PHI shared with Meta, Google, TikTok. OCR Breach Portal submitted March 1, 2023.
California Lawyers Association · medium trust · accessed 2026-05-21
GoodRx: $1.5M civil penalty for first enforcement under Health Breach Notification Rule. BetterHelp: $7.8M for failing to implement reasonable safeguards while sharing data with Facebook and Criteo.
Alliance Risk · low trust · accessed 2026-05-21
Standard structure $1M/$1M for small businesses. Healthcare/finance carry $5M+. Funds transfer fraud often capped $100,000–$250,000. Ransomware BI may not activate until 8-24 hours after incident.
CoverHound · low trust · accessed 2026-05-21
General range $500–$5,000/year. 'Average cost of a healthcare data breach is currently $9.77 million.'
Mintz · high trust · accessed 2026-05-21
June 2025 OIG advisory opinion on MSO-managed physician practice engaging telehealth companies for GLP-1. Requirement: 'compensation is consistent with fair market value in arms-length transactions, and the compensation does not take into account the volume or value of any referrals.'
Partnership for Safe Medicines · medium trust · accessed 2026-05-21
Hims & Hers 2024 10-K + 2025 10-K expansion: FDA findings of misleading promotional statements 'can lead to private litigation under federal and state consumer protection and unfair trade practices laws.'
U.S. Supreme Court (via Justia) · high trust · accessed 2026-05-21
Court held §503A's provisions regarding advertisement and promotion of compounded drugs unconstitutional restrictions on commercial speech under Central Hudson.
Holland & Knight LLP · high trust · accessed 2026-05-21
September 9, 2025 FDA and HHS announced broad initiative. FDA 'sending thousands of letters warning pharmaceutical companies' plus approximately 100 cease-and-desist letters.
Wilson Sonsini Goodrich & Rosati · high trust · accessed 2026-05-21
More than 50 warning letters issued primarily September 9, 2025. Named recipients include Expert Aesthetics, Bioverse, Tuyo Health, GLP-1 Solution.
U.S. Food and Drug Administration · high trust · accessed 2026-05-21
FDA Warning Letter database lists telehealth/compounder recipients dated 09/09/2025 including Healthon, Bioverse, Tuyo Health, GLP-1 Solution, SemaBio, Vitals RX, Fancy Meds, DirectMeds, JulyMD, Slendid, Try Nova, eDrugstore.
Medical Devices and Pharma · medium trust · accessed 2026-05-21
March 3, 2026: 30 warning letters. Four flagged patterns: implying compounded GLP-1 are same as FDA-approved, suggesting equivalence, obscuring product sourcing, advertising under telehealth brand names.
Drug Topics · medium trust · accessed 2026-05-21
FDA sent 30 warning letters February 20, made public March 3, 2026. Common violations: claims implying sameness with FDA-approved weight loss drugs.
Holland & Knight LLP · high trust · accessed 2026-05-21
April 2025: Lilly filed four lawsuits in N.D. California against Fella Health, Willow Health, Henry Meds, and Mochi Health.
Law Commentary · medium trust · accessed 2026-05-21
Novo Nordisk filed federal patent infringement lawsuit February 9, 2026 in D. Delaware. Lawsuit later voluntarily dismissed; Hims will no longer advertise compounded GLP-1.
Pharma Now · medium trust · accessed 2026-05-21
Sept 9 2025 enforcement targeted Tuyo Health and Bioverse for claims 'Same active as Wegovy and Ozempic.'
Cooley LLP · high trust · accessed 2026-05-21
FTC December 2022 Guidance requires 'competent and reliable scientific evidence' for any health-related claim, generally 'randomized, controlled human clinical testing.'
National Law Review · medium trust · accessed 2026-05-21
FTC alleged NextMed used fake testimonials and unfairly distorted consumer reviews. Subscription costs $138-188 did not properly disclose drug exclusion. Final order $150,000 December 3, 2025.
Alston & Bird LLP · high trust · accessed 2026-05-21
December 3, 2025 FTC final order against NextMed and its principals — fake testimonials, distorted reviews, undisclosed costs, failure to obtain express informed consent for recurring debits.
Arnold & Porter LLP · high trust · accessed 2026-05-21
FTC finalized revisions to Endorsement Guides at 16 CFR Part 255, published July 26, 2023. Expanded definition of 'endorsement' to cover likeness depictions, tags, mentions. Both advertiser and influencer can be liable.
Cornell Legal Information Institute · high trust · accessed 2026-05-21
Endorsements depicting non-typical experience must 'clearly and conspicuously disclose the generally expected performance.' Simple 'Results not typical' disclaimers are insufficient.
Cornell Legal Information Institute · high trust · accessed 2026-05-21
Endorser connections 'might materially affect the weight or credibility of the endorsement' must be 'disclosed clearly and conspicuously.'
Meta Platforms Inc. · high trust · accessed 2026-05-21
'Advertisers can't run ads that promote prescription drugs unless they are actively certified by LegitScript.' Permitted countries: US, Canada, New Zealand. Age targeting: 18+.
EHM Results · low trust · accessed 2026-05-21
Meta introduced stricter advertising rules for healthcare in 2025. Health and wellness are 'sensitive categories.'
eMarketer/Insider Intelligence · medium trust · accessed 2026-05-21
35 state attorneys general are pushing Meta for tighter enforcement amid 'surge of misleading marketing for weight loss products' on Facebook and Instagram.
Google LLC · high trust · accessed 2026-05-21
Online pharmacies must be 'accredited by LegitScript Healthcare Merchant Certification Program.' Promotion of unapproved pharmaceuticals prohibited.
Google LLC · high trust · accessed 2026-05-21
April 2026: Google Ads updates to allow certified online pharmacies to promote prescription drug services in India; LegitScript expansion.
Search Engine Land · medium trust · accessed 2026-05-21
Starting October 29, Google will allow advertisers to include prescription drug terms in ad text in 'limited, non-promotional contexts.'
TikTok Inc. · high trust · accessed 2026-05-21
Prohibits: pharmaceuticals, healthcare products, medical institutions, online pharmacies and telehealth providers, therapy/mental health consulting.
Accelerated Digital Media · low trust · accessed 2026-05-21
Comparative 2026 summary across Meta, TikTok, Google, Microsoft, Reddit, Snapchat showing strictest TikTok restrictions.
X Corp. · high trust · accessed 2026-05-21
X restricts promotion of health and pharmaceutical products. Prohibits creation of custom audiences or conversion events based on sensitive health information.
Bloomberg Government · high trust · accessed 2026-05-21
FDA invoked 2013 federal statute amendment at §502(bb). Bill S. 652 would extend FDA jurisdiction over social-media influencers and telehealth companies.
Foley & Lardner LLP · high trust · accessed 2026-05-21
Sens. Durbin (D-IL) and Marshall (R-KS) introduced bipartisan Protecting Patients from Deceptive Drug Ads Act (S. 652) in February 2025.
STAT News · high trust · accessed 2026-05-21
FDA sent 'more than 50 warning letters' in September 2025. Hims & Hers's Super Bowl GLP-1 ad called out for 'parody[ing] the benefits of GLP-1 drugs without any mention of side effects.'
FindLaw (Thomson Reuters) · high trust · accessed 2026-05-21
It is unlawful for any licensed person 'to disseminate or cause to be disseminated any advertisement that is in any manner false or misleading.' Use of model photo without 'prominent location in easily readable type' is a violation. Violations are misdemeanors.
Texas Medical Board · high trust · accessed 2026-05-21
'No physician shall disseminate or cause the dissemination of any advertisement that is in any way false, deceptive, or misleading.' Photos of models or actors must be 'explicitly identified as models and not actual patients.'
Texas Medical Association · high trust · accessed 2026-05-21
TMB defines testimonial as 'an attestation or implied attestation to the competence of a physician's service.' AMA and TMA ethics policy conclude testimonials 'tend to be deceptive.'
Florida Board of Medicine · high trust · accessed 2026-05-21
'No physician shall disseminate or cause the dissemination of any advertisement which is in any way false, deceptive, or misleading.' Licensee name must 'clearly identify…as either MD, PA, or AA.'
New York State Department of Health · high trust · accessed 2026-05-21
Section 27: improper advertising includes 'false, fraudulent, deceptive, misleading, sensational, or flamboyant.' Testimonials in physician marketing materials strictly prohibited in NY even with consent and anonymity. Must maintain exact copy of each advertisement for one year.
Cornell Legal Information Institute · high trust · accessed 2026-05-21
Covered entity must obtain authorization for any use or disclosure of PHI for marketing, except face-to-face and nominal-value promotional gifts. When marketing involves financial remuneration from third party, 'the authorization must state that such remuneration is involved.'
U.S. Department of Health and Human Services · high trust · accessed 2026-05-21
HIPAA Privacy Rule gives individuals important controls over whether and how their PHI is used and disclosed for marketing purposes.
LegitScript · high trust · accessed 2026-05-21
LegitScript Healthcare Merchant Certification 'is required by many major credit cards and internet platforms.' Pricing: 'one-time application fee and annual certification fee per website.'
Bloom Consulting Agency · low trust · accessed 2026-05-21
LegitScript evaluates applicants against 9 standards covering compliance, transparency, business affiliations, patient best practices.
U.S. Food and Drug Administration · high trust · accessed 2026-05-21
FDA-maintained list of bulk drug substances placed in Category 2 of interim 503A bulks list. FDA's position is Category 2 means 'do not compound.'
Lexology · medium trust · accessed 2026-05-21
BPC-157 and Thymosin Beta-4 added to Category 2 on September 29, 2023. Ipamorelin acetate removed September 27, 2024. PCAC reconsideration July 23-24, 2026.
Frier Levitt LLP · high trust · accessed 2026-05-21
RUO peptides cannot be used in human or veterinary compounding. RUO disclaimer 'is a ruse to avoid FDA scrutiny.'
NexaMed · low trust · accessed 2026-05-21
Compliant copy advertises consultations and patient wellness goals rather than specific compound names. 'Personalized wellness programs for men over 40' clears platform review; 'Buy sermorelin online' does not.
Hims & Hers Health, Inc. Investor Relations · high trust · accessed 2026-05-21
Subscribers grew to over 2.5 million, up 13% YoY. Full year 2025 MORPAS $83/month (28% YoY from $65). Gross margin 74%. Marketing $919.3M (39.2% of revenue). Net income $128M; Adjusted EBITDA $318M. Revenue $2.35B, up 59% YoY.
U.S. Securities and Exchange Commission · high trust · accessed 2026-05-21
FY2025 annual report disclosing $2.35B revenue, 2.5M subscribers, 74% gross margin, 39.2% marketing. Hers brand accounted for nearly 40% of US revenue in 2025; personalized offerings over 70% of US revenue.
The Motley Fool · high trust · accessed 2026-05-21
Q1 2026: Revenue $608M, subscribers 2.6M, gross margin 65% GAAP / 70% adjusted, marketing 36% of revenue, Adjusted EBITDA $44M, GAAP net loss $92M. Discontinued compounding product advertising March 2026.
AlphaPilot · medium trust · accessed 2026-05-21
Q1 2026 revenue $608M, 2.6M subscribers, Adjusted EBITDA $44M. US revenue declined 8% YoY to $529.9M while rest-of-world surged ~10x to $78.2M.
PR Newswire / Novo Nordisk · high trust · accessed 2026-05-21
Press release announcing Novo Nordisk's termination of direct-sale collaboration with Hims & Hers.
Fierce Healthcare · high trust · accessed 2026-05-21
Stock dropped ~30% on announcement, contextualizing financial-model impact of losing compounded-GLP-1 revenue base.
Pharmacy Times · high trust · accessed 2026-05-21
FDA resolved tirzepatide shortage December 19, 2024; 503B given 90-day transition ending March 19, 2025.
The National Law Review · high trust · accessed 2026-05-21
Seven peptides removed from Category 2 on April 15, 2026 following nomination withdrawals, but removal does NOT authorize compounding. PCAC meeting July 23-24, 2026.
HealingMaps · medium trust · accessed 2026-05-21
FDA PCAC meeting July 23-24, 2026 will consider seven peptides for 503A bulks list inclusion. Public comment docket FDA-2025-N-6895 open until July 22, 2026.
U.S. Food & Drug Administration · high trust · accessed 2026-05-21
Official FDA advisory committee meeting calendar entry for PCAC review of peptide bulks-list candidates July 23-24, 2026.
Hospitalogy · medium trust · accessed 2026-05-22
HIMS weight-loss specialty achieved 70% subscriber retention at week 12 (vs 42% industry baseline per Blue Health Intelligence) and 85% at week 4.
Riyado Sofian / RS Capital · medium trust · accessed 2026-05-22
HIMS Q2 2025: CAC $2,581/new subscriber (highest ever recorded), 73K new subscribers off $188M marketing spend. Marketing 40% of revenue.
Kroker Equity Research · medium trust · accessed 2026-05-22
Estimated 2024 HIMS blended CAC ~$89 vs LTV ~$338 (~4:1 LTV:CAC). FY2024 marketing $679M (~46%).
Hims & Hers · high trust · accessed 2026-05-22
Compounded semaglutide begins at $199/mo on 6-month prepaid plan. Active Hims Weight Loss Membership required ($39 first month, $149/month thereafter).
Policy Lab · low trust · accessed 2026-05-22
April 2026: OnlineSemaglutide.org $242/mo, Noom Med $149 first month then $299/mo, TrimRx $279/$283-399/mo, Shed $299-399/mo by dose, Ro $39 first month then $74-149/mo membership.
Healthy Meals Incentives · low trust · accessed 2026-05-22
Compounded semaglutide from licensed 503A/503B pharmacies typically runs $200-500/month in 2026, plus $40-100 in membership/consultation fees.
Peptide News Digest · low trust · accessed 2026-05-22
BPC-157: $40/mo to $500/mo. TB-500: $25/vial to $500/mo. Sermorelin: $79-500/mo. Ipamorelin/CJC-1295 combo: $200-600/mo through clinics, $80-150/mo from research vendors.
PeakedLabs · low trust · accessed 2026-05-22
Standard BPC-157 protocol (500mcg/day) runs about $120-160/month from verified vendors; research peptide vendors $30-120 per vial.
RethinkPeptides · low trust · accessed 2026-05-22
Corroborates BPC-157 status post-Category-2-removal and PCAC review timing.
ParcelPath · medium trust · accessed 2026-05-22
FedEx Priority Overnight starts at $48.59 for 5-pound package to Zone 2. Packages up to 5 lbs range $50-70 depending on zone.
ParcelPath · medium trust · accessed 2026-05-22
Effective January 5, 2026: FedEx implements mandatory $8.50 dangerous-goods surcharge per package containing dry ice. January 2026 general rate increase 5.9%.
The FDA Group · medium trust · accessed 2026-05-21
FDA guidance recommends firms submit response within 15 business days after 483. Consent decrees usually imposed as result of continual non-conformance.
Frier Levitt · medium trust · accessed 2026-05-21
Summary suspension available when 'clear and convincing threat of immediate and serious harm to others' under R.C. §4729.571. Pharmacies have only 30 days to request hearing under Chapter 119.
Frier Levitt · medium trust · accessed 2026-05-21
Over the past year, Ohio Board of Pharmacy issued summary suspension orders involving clinics where peptide products (AOD-9604, BPC-157, ipamorelin) were identified.
Terms.law · medium trust · accessed 2026-05-21
Reserve hold period typically 90 to 180 days. MATCH listings last 5 years from placement. Removal requires processor-initiated action, issue resolution, legal action, or automatic expiration.
TFM Law · medium trust · accessed 2026-05-21
Bank reserves right to hold funds for up to 180 days. The 180 days corresponds to the chargeback liability period.
Chargeback Gurus · medium trust · accessed 2026-05-21
MATCH List entries remain active for five years from date added. Duration set by Mastercard and applies across all reason codes.
Griffith E. Harris Insurance Services · medium trust · accessed 2026-05-21
Tail coverage typically 2.5 to 3 times annual premium. One-time payment 100% to 300% of annual malpractice premium.
The Doctors Company · high trust · accessed 2026-05-21
Costs range from full year's annual premium to multiple of annual premium. The Doctors Company offers multiple options including earned retirement tail and installment over two years interest-free.
Food and Drug Law Institute (FDLI) · high trust · accessed 2026-05-21
Park Doctrine imposes strict, vicarious criminal liability on RCOs for misdemeanor FDCA violations without proof of personal participation, intent, or knowledge.
LegalClarity · medium trust · accessed 2026-05-21
Supreme Court approved application in 1975 United States v. Park. Officer must have held position of responsibility and had power to prevent or correct violation.
Internal Revenue Service · high trust · accessed 2026-05-21
Responsible person has 'duty to perform and power to direct the collecting, accounting, and paying of trust fund taxes.' 'Business does not have to have stopped operating' for TFRP to be assessed.
Tax Law Offices · low trust · accessed 2026-05-21
Closing a business does not automatically wipe out its payroll tax debts. TFRP follows the responsible person, not just the business entity.
Healthcare Law Insights · medium trust · accessed 2026-05-21
At least 45 days in advance of closure, pharmacies must provide written notice to patients that have received prescription within the last year.
California State Board of Pharmacy · high trust · accessed 2026-05-21
Written notice to patients 45 days before closure. Contact Board prior to transferring or selling drug inventory. Submit Discontinuance of Business form (17M-8) within 10 days.
Tavrn · medium trust · accessed 2026-05-21
California 7 years per 22 CCR §72543. Texas 7 years per 22 TAC §163.2. Florida 5 years per 64B8-10.002. New York 6 years per 10 NYCRR §405.10. Pennsylvania 7 years. Washington 10 years for physicians; 26 years for hospitals. New Mexico permanent.
DEA Diversion Control Division · high trust · accessed 2026-05-21
Pharmacy must maintain controlled substance records for at least 2 years. Schedule II separate; Schedule III-V 'readily retrievable.'
Cariend · medium trust · accessed 2026-05-21
Connecticut: 3+ months; newspaper twice seven days apart. Delaware: 3 months + first-class mail. Illinois: 30 days. Michigan: 30 days written.
GlobeNewswire / WW International · high trust · accessed 2026-05-21
$132 million transaction, inclusive of minimum $26 million Sequence cash; net purchase price $106 million. ~$25M ARR, ~24,000 members. Implied multiple ~5.3x.
Subscription Insider · medium trust · accessed 2026-05-21
WW acquired Sequence for $132 million inclusive of minimum $26 million cash. Effective net purchase price $106 million.
ElevenFlo · low trust · accessed 2026-05-21
WeightWatchers filed for chapter 11 May 6, 2025; confirmed plan June 17, 2025 (42 days). Plan eliminated ~$1.15B of ~$1.6B prepetition debt.
SmartCompany · medium trust · accessed 2026-05-21
Eucalyptus being acquired by Hims & Hers Health in deal worth US$1.15 billion (AU$1.6 billion). >US$450 million ARR. US$240 million closing payment, deferred over 18 months, earn-outs through 2029.
Fierce Healthcare · medium trust · accessed 2026-05-21
Hims & Hers acquired Seaview Enterprises (MedisourceRx, 503B) in 2024; peptide manufacturing assets from C S Bio Feb 2025; ZAVA June 2025; Eucalyptus Feb 19 2026 for $1.6 billion.
Nelson Advisors · medium trust · accessed 2026-05-21
Average revenue multiple for HealthTech in 2025: 4-6x. EV/EBITDA 10-14x (up from 10-12.5x in 2024). Teladoc compressed from ~33.2x EV/Revenue (FY2020) to ~0.7x (FY2024).
Rock Health · medium trust · accessed 2026-05-21
M&A activity surged to 195 deals in 2025, up 61% from 2024. Digital health companies 66% of acquirers. PE firms 10% of all deals.
CTOL Digital Solutions · low trust · accessed 2026-05-21
Novo Nordisk abruptly terminated two-month-old partnership with Hims & Hers in June 2025. Hims shares plummeted over 32%.
Fierce Healthcare · medium trust · accessed 2026-05-21
April 2025 Lilly filed four lawsuits in N.D. California against Fella Health, Willow Health, Henry Meds and Mochi Health.
Courthouse News Service · medium trust · accessed 2026-05-21
Judge Jacqueline Scott Corley partially denied Mochi Health's bid to dismiss Lilly's complaint, allowing Lanham Act and UCL claims to proceed.
The RX Index Research · medium trust · accessed 2026-05-21
As of late February 2026, over 4,400 GLP-1-related lawsuits filed. MDL 3094 consolidates product-liability lawsuits in E.D. Pennsylvania. As of May 1, 2026 JPML report, 3,636 cases pending.
Vanta · medium trust · accessed 2026-05-21
Under HIPAA Breach Notification Rule, covered entities experiencing breach affecting 500+ individuals must notify HHS without unreasonable delay and no later than 60 days following discovery.
Accountable HQ · low trust · accessed 2026-05-21
If breach affects 500 or more individuals, covered entities must notify Secretary without unreasonable delay and no later than 60 days following breach.
HIPAA Journal · medium trust · accessed 2026-05-21
HIPAA Breach Notification Rule requires notification of breaches affecting fewer than 500 individuals via OCR breach reporting tool no later than 60 days after end of calendar year.
Palatin Technologies · high trust · accessed 2026-05-22
NDA 210557 for Vyleesi (bremelanotide) approved June 21, 2019. First as-needed treatment approved by FDA for premenopausal women with HSDD. Prefilled autoinjector pen self-administered into abdomen or thigh.
U.S. Food and Drug Administration · high trust · accessed 2026-05-22
Drugs@FDA primary listing for NDA 210557, Vyleesi (bremelanotide injection). Approved June 21, 2019 for premenopausal acquired generalized HSDD.
Federal Register · high trust · accessed 2026-05-22
FDA notice confirming Vyleesi NDA 210557 approval date June 21, 2019; Palatin Technologies as sponsor.
U.S. Food and Drug Administration · high trust · accessed 2026-05-22
October 8, 2019: FDA approved Clinuvel's SCENESSE (afamelanotide 16mg) implant for prevention of phototoxic reactions in EPP. MC1R agonist.
Drugs.com · medium trust · accessed 2026-05-22
SCENESSE (afamelanotide), Clinuvel, NDA 210797, approved October 8, 2019 for EPP.
Aetion FDA Decision Alerts · medium trust · accessed 2026-05-22
October 8, 2019, FDA granted approval to Clinuvel's SCENESSE 16mg implant for EPP.
U.S. Food and Drug Administration · high trust · accessed 2026-05-22
Egrifta (tesamorelin for injection), Theratechnologies, approved November 10, 2010 for HIV lipodystrophy.
Theratechnologies Inc. · high trust · accessed 2026-05-22
March 2025: FDA approved sBLA for F8 formulation of tesamorelin. EGRIFTA WR is daily injectable, weekly reconstitution. Less than half administration volume of F4.
Infectious Disease Advisor · medium trust · accessed 2026-05-22
Egrifta WR is the only medication approved in the U.S. for reduction of excess abdominal fat in adults with HIV who have lipodystrophy.
Stealth BioTherapeutics Inc. · high trust · accessed 2026-05-22
September 19, 2025: FDA granted accelerated approval to FORZINITY (elamipretide) injection, NDA 215244, for adult and pediatric Barth syndrome patients weighing at least 30 kg. Dose 40 mg subcutaneous once daily.
United Mitochondrial Disease Foundation · medium trust · accessed 2026-05-22
Elamipretide (formerly SS-31) FDA-approved Sept 2025 as first FDA-approved Barth syndrome treatment. Four-amino-acid cell-penetrating peptide targeting inner mitochondrial membrane cardiolipin.
U.S. Food and Drug Administration · high trust · accessed 2026-05-22
Drugs@FDA primary record for elamipretide / FORZINITY, NDA 215244. Accelerated approval based on TAZPOWER trial intermediate endpoint — knee extensor muscle strength improvement of 45%+.
Johns Hopkins University Hub · medium trust · accessed 2026-05-22
September 19, 2025: Stealth BioTherapeutics' FORZINITY becomes first FDA-approved Barth syndrome treatment. Patient population approximately 150 in the US.
PR Newswire / Eli Lilly · high trust · accessed 2026-05-22
Eli Lilly announced positive topline results from TRIUMPH-1 Phase 3 obesity trial; participants on 12 mg retatrutide losing average 70.3 lbs (28.3%) over 80 weeks.
RetaWeightLoss · low trust · accessed 2026-05-22
Q4 2026 is earliest plausible NDA filing window for retatrutide. Submission anchored by TRIUMPH-1 and TRIUMPH-2 data. Standard 10-12 month FDA review cycle. Potential approval decision 2027.
Honest Care · low trust · accessed 2026-05-22
Lilly has indicated plans to submit NDA for retatrutide in 2026; Q4 2026 represents analyst projections.
Superpower · low trust · accessed 2026-05-22
Araim Pharmaceuticals has closed, no active IND exists as of April 2026. ARA-290 is not FDA-approved for any human indication.
Foundation for Sarcoidosis Research · medium trust · accessed 2026-05-22
Araim Pharmaceuticals developed ARA-290 through Phase 2 for sarcoidosis-associated small-fiber neuropathy. Received FDA orphan drug designation. No Phase 3 development progressed before company closure.
PMC / National Library of Medicine · high trust · accessed 2026-05-22
Phase 2 clinical trial of cibinetide (ARA-290) for diabetic macular edema.
Therapeutic Goods Administration (TGA), Australia · high trust · accessed 2026-05-22
TGA issued 27 infringement notices totalling AUD $101,412 to a NSW individual for unlawful supply of Melanotan II in contravention of the Therapeutic Goods Act 1989.
Medicines and Healthcare products Regulatory Agency (UK) · high trust · accessed 2026-05-22
United Kingdom banned both Melanotan I and Melanotan II in 2019, making their sale, supply, and possession illegal.
U.S. Food and Drug Administration · high trust · accessed 2026-05-22
FDA enforcement docket for Melanotan-related conduct. References August 30, 2007 FDA warning letter to Melanocorp.
Eden Health · high trust · accessed 2026-05-22
Direct fetch of Eden's home page confirms peptide-adjacent menu: GLP-1 treatments, Sermorelin (injection + tablet), GHK-Cu Foam (topical, hair growth). Eden does NOT offer BPC-157, TB-500, PT-141, KPV, MOTS-C, CJC-1295, ipamorelin, tesamorelin, semax, selank, DSIP, Epitalon, or Melanotan.
Good Life Meds · high trust · accessed 2026-05-22
Direct fetch confirms Good Life Meds' entire injectable peptide-adjacent menu: Sermorelin, NAD+ Injections, NAD+ Nasal Spray, Microdose GLP-1. Good Life Meds does NOT offer BPC-157, TB-500, PT-141, KPV, MOTS-C, CJC-1295, Ipamorelin, Tesamorelin, GHK-Cu, Semax, Selank, Melanotan, DSIP, or Epitalon.
U.S. Department of Justice · high trust · accessed 2026-05-22
DOJ peptide-distribution prosecution. Establishes federal criminal prosecution as live enforcement tool in peptide-distribution space.
AMC Defense Law · medium trust · accessed 2026-05-22
Tailor Made Compounding was prosecuted by DOJ for distributing unapproved peptides including BPC-157, forfeited $1.79 million. The case established federal government willingness to bring CRIMINAL charges.
The Peptide Catalog · low trust · accessed 2026-05-22
Tailor Made Compounding and founder Jeremy Delk pleaded guilty October 2020 — distributing unapproved new drugs. Substances named: BPC 157, Cerebrolysin, CJC 1295, DSIP, Epitalon, GW 501516, Ipamorelin, LGD-4033, LL-37, Melanotan II, MK 677, PEG-MGF, Selank, Semax. Sentence: three years' probation; forfeiture $1,788,906.82.
Policy Canary · medium trust · accessed 2026-05-22
Seven warning letters dated March 31, 2026 (published April 7 2026) by CDER: Pink Pony Peptides, Mile High Compounds, Prime Sciences, Gram Peptides, PekCura Labs, FormPour, Guangzhou Huli Technology.
U.S. Food and Drug Administration · high trust · accessed 2026-05-22
FDA warning letter 721806 to Gram Peptides, dated March 31, 2026. Verbatim: 'Despite statements on your product labeling marketing your products for Research Use Only, evidence obtained from your website establishes that your products are intended to be drugs.'
U.S. Food and Drug Administration · high trust · accessed 2026-05-22
FDA warning letter 695607 dated December 10, 2024 — Summit Research Peptides. Part of December 2024 RUO-vendor wave including Prime Peptides, Xcel Peptides, SwissChems.
Health Law Alliance · medium trust · accessed 2026-05-22
September 2025: FDA issued series of letters regarding peptides sold as RUO. Peptides named in 2025 actions: Semaglutide, Tirzepatide, Retatrutide, BPC-157, SARMs, Trendione.
Peptide Examiner · low trust · accessed 2026-05-22
FDA position from multiple 2024-2025 warning letters: RUO labeling is 'a ruse to avoid FDA scrutiny.' Intended Use Doctrine: if product is being sold for human injection, the label does not matter.
Corepay · medium trust · accessed 2026-05-22
Mastercard June 2025 bulletin GLB 11691.1 outlines enhanced BRAM enforcement. Red flags: 'GLP-1 for weight loss' on unapproved products, selling research peptides alongside bodybuilding claims, bundles with prescription-only ingredients. Automated systems terminate accounts and freeze funds 90-180 days.
Vector Payments · low trust · accessed 2026-05-22
Two real pathways: research-only ecommerce vs LegitScript-supported clinic/telehealth. Hybrid Rx+RUO treated as highest-risk.
SeaPort Insurance Service · medium trust · accessed 2026-05-22
Standard malpractice insurance categorically excludes coverage for unapproved medications. Standard policies contain clear exclusions for 'experimental' or 'investigational' treatments.
SeaPort Insurance Service · medium trust · accessed 2026-05-22
Telehealth peptide insurance risk includes peptide malpractice underwriting risk and peptide clinic regulatory defense coverage.
Elite NP · low trust · accessed 2026-05-22
April 2026 FDA announcement removes 12 peptides from Category 2 to PCAC review: BPC-157, Thymosin beta-4, Epitalon, GHK-Cu, MOTS-c, DSIP (Emideltide), Semax. Includes Semax but NOT Selank.
Better Med Spa · low trust · accessed 2026-05-22
Better Med Spa offers Semax + Selank (NeuroFocus & Flow) for cognitive enhancement, focus, anxiety reduction.
Iowa IV · low trust · accessed 2026-05-22
Iowa IV offers Semax/Selank peptide combination for focus, memory, emotional balance, cognitive performance.
Beverly Hills Rejuvenation Center · low trust · accessed 2026-05-22
Combination blend marketed as recovery / wound-healing stack. Documents 'KLOW' combination: KPV + GHK-Cu + BPC-157 + TB-500.
Biogenic Foods · low trust · accessed 2026-05-22
KLOW blend marketed as research peptide combining GHK-Cu + BPC-157 + TB-500 + KPV. Composition varies by vendor.
Preferred Regen ATL · low trust · accessed 2026-05-22
Documents BPC-157 + TB-500 + KPV + GHK-Cu combination as recovery/regeneration peptide stack.
Tactus Health · high trust · accessed 2026-05-22
Direct fetch of tactushealth.com on May 22 2026 confirms Tactus Health is 'available in all states except California and Mississippi.' Material geographic constraint suggests state-level pharmacy/prescriber rules drove the carve-out (CA's July 1 2026 PIC rule per §2 the likely CA driver).
Federal Trade Commission · high trust · accessed 2026-05-22
On December 3, 2025 the FTC approved a final order against telehealth weight-loss provider NextMed (Robert Epstein and Frank Leonardo named individually), requiring $150,000 in monetary relief for unsubstantiated weight-loss claims, fake testimonials, distorted consumer reviews, undisclosed subscription costs ($138-188/month subscription that did NOT include GLP-1 drug or required labs), and failure to obtain express informed consent for recurring debits.